Christopher McNair, PhD, on Decreases in Cancer-Related Care Due to COVID-19

Aug 13, 2020

Video

A study published in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients being seen for cancer-related care due to the COVID-19 pandemic.

Researchers from the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) found significant decreases nationwide in the number of patients being seen for cancer-related care as a result of the coronavirus disease 2019 (COVID-19).

The study, published in JCO Clinical Cancer Informatics, found the most significant decline in encounters to be those related to new cancer incidences, including screening, initial diagnosis, second opinion, and treatment initiation appointments.

“The COVID-19 pandemic has had a tremendous immediate impact on the world, and it is clear that there will be effects for years to come,” the authors wrote. “Ultimately, these observed trends have serious implications for future cancer care and validate the need to study and monitor the effect of COVID-19 mitigation on cancer diagnosis and treatment moving forward.

In an interview with CancerNetwork®, Christopher McNair, PhD, director of Cancer Informatics and assistant professor in the Department of Cancer Biology at SKCC, discussed the study findings and the possible future implications for patients with cancer should these trends continue.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. JCO Clinical Cancer Informatics. doi: 10.1200/CCI.20.00068

Related Content

Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy.

Longer Surgery Delay After CRT Does Not Improve Esophageal Cancer Responses

September 23rd 2023

Article

Data from the NeoRes II trial caution against routinely delaying surgery for more than 6 weeks after patients with resectable locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023

Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Ribociclib/Aromatase Inhibitors Maintain HRQOL in HR+, HER2– Breast Cancer

September 22nd 2023

Article

A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

September 4th 2023

Podcast

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

The regulatory decision for elacestrant in European patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer and an activating ESR1 mutation was based on data from the phase 3 EMERALD study.

Elacestrant Earns EU Approval for ESR1+, ER+, HER2– Advanced Breast Cancer

September 22nd 2023

Article

The regulatory decision to approve elacestrant in European patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer and an activating ESR1 mutation was based on data from the phase 3 EMERALD study.